We Just Learned Something New About Ensysce Biosciences Inc. (NASDAQ: ENSC) This Week With Its -20.98% Loss – Marketing Sentinel
Home  »  Company   »  We Just Learned Something New About Ensysce Biosci...

We Just Learned Something New About Ensysce Biosciences Inc. (NASDAQ: ENSC) This Week With Its -20.98% Loss

During the last session, Ensysce Biosciences Inc. (NASDAQ:ENSC)’s traded shares were 0.53 million, with the beta value of the company hitting -0.11. At the end of the trading day, the stock’s price was $0.67, reflecting an intraday gain of 1.77% or $0.01. The 52-week high for the ENSC share is $17.12, that puts it down -2455.22 from that peak though still a striking 7.46% gain since the share price plummeted to a 52-week low of $0.62. The company’s market capitalization is $16.51M, and the average intraday trading volume over the past 10 days was 0.9 million shares, and the average trade volume was 885.13K shares over the past three months.

Ensysce Biosciences Inc. (NASDAQ:ENSC) trade information

Ensysce Biosciences Inc. (ENSC) registered a 1.77% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.77% in intraday trading to $0.67 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is -20.98%, and it has moved by -42.59% in 30 days. Based on these gigs, the overall price performance for the year is -94.86%. The short interest in Ensysce Biosciences Inc. (NASDAQ:ENSC) is 0.14 million shares and it means that shorts have 0.36 day(s) to cover.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Ensysce Biosciences Inc. (ENSC) estimates and forecasts

Statistics show that Ensysce Biosciences Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Ensysce Biosciences Inc. (ENSC) shares have gone down -70.28% during the last six months, with a year-to-date growth rate more than the industry average at 43.92% against -0.10.

Revenue for the current quarter is expected to be $1 million as predicted by 2 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to $1.1 million by the end of Mar 2022.

While earnings are projected to return 978.50% in 2022.

ENSC Dividends

Ensysce Biosciences Inc. is due to release its next quarterly earnings on November 15. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Ensysce Biosciences Inc. (NASDAQ:ENSC)’s Major holders

Ensysce Biosciences Inc. insiders own 67.16% of total outstanding shares while institutional holders control 13.92%, with the float percentage being 42.40%. HG Vora Capital Management, LLC is the largest shareholder of the company, while 19 institutions own stock in it. As of Dec 30, 2021, the company held over 2.46 million shares (or 10.15% of all shares), a total value of $11.57 million in shares.

The next largest institutional holding, with 0.3 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 1.24% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $1.42 million.

Also, the Mutual Funds coming in first place with the largest holdings of Ensysce Biosciences Inc. (ENSC) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 0.21 million shares. This amounts to just over 0.85 percent of the company’s overall shares, with a $0.97 million market value. The same data shows that the other fund manager holds slightly less at 90901.0, or about 0.37% of the stock, which is worth about $0.43 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts